Back to search

North Dakota State University

Rage (Receptor for Advanced Glycation End Products) in Melanoma Progression

Abstract

dc:description.abstract

The Receptor for Advanced Glycation End Products (RAGE) and its ligands are expressed in multiple cancer types and are implicated in cancer progression. Our lab has previously reported higher transcript levels of RAGE and S100B in advanced staged melanoma patients. The contribution of RAGE in the pathophysiology of melanoma has not been well studied. Based on previous reports, we hypothesized that RAGE, when over-expressed in melanoma cells, promotes melanoma progression. To study the pathogenic role of RAGE in melanoma, a primary melanoma cell line, WM115, was selected and stably transfected with full length RAGE (FL_RAGE) to generate a model cell line over-expressing RAGE (WM115_RAGE). WM266, a sister cell line of WM115, originated from a metastatic tumor of the same patient was used as a metastatic control cell line in the study. After assessing the expression levels of RAGE in the transfected cells, the influence of RAGE on their cellular properties was examined. An enhanced motility but suppressed proliferation of WM115 cells was found after RAGE over-expression, these properties could be reversed upon suppression of RAGE in these cells. We next explored the mechanisms of RAGE induced changes in cell proliferation and migration in WM115_RAGE cells and found a significant upregulation in S100B protein in the WM115_RAGE melanoma cells compared to the MOCK cells. However, S100B suppression produced no effect on WM115_RAGE cells motility. Furthermore, expression of tumor suppressor p53 protein, which is one of the target proteins of S100B, was found to be significantly reduced in WM115 cells after RAGE over-expression. We also investigated the effect of RAGE over-expression on melanoma tumor growth and deciphered the downstream signaling involved. We found a significantly larger tumor growth rate of the WM115_RAGE cells compared to the control cells. S100B, S100A4, S100A6 and S100A10 proteins that are relevant in melanoma pathophysiology, were found to be upregulated in WM115_RAGE tumors compared to MOCK tumors. Moreover, enhanced AKT and ERK signal activation was observed in WM115_RAGE tumors as compared to MOCK tumors. Finally, anti-RAGE antibody treatment significantly suppressed tumor growth, which could be further enhanced by combining the antibody with the chemotherapeutic drug dacarbazine.

Degree

thesis:*
Grantor dc:publisher
North Dakota State University
Year dc:date.issued
2014

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Meghnani, Varsha

Rights

dc:rights
Statement dc:rights
  • NDSU Policy 190.6.2

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/10365/27415

Chain of custody

source
Harvested from
North Dakota State University
Base URL
library.ndsu.edu/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Meghnani, Varsha. Rage (Receptor for Advanced Glycation End Products) in Melanoma Progression. North Dakota State University, 2014. https://hdl.handle.net/10365/27415